In some embodiments, a self-monitoring intravenous catheter system is provided. An alarm controller is provided that receives signals representing a pH value, an oxygen saturation value, and a pressure value in proximity to the distal end of the catheter. By performing a fuzzy logic analysis of the values, the alarm controller is able to detect that the catheter is about to fail or has failed, and can cause alerts to be presented. In some embodiments, an intravenous catheter is provided that has a pH sensor and an oximeter disposed at a distal end of the catheter to obtain the pH value and oxygen saturation values analyzed by the alarm controller. Embodiments of the catheter and self-monitoring intravenous catheter system may be particularly useful in treating neonates, who are sensitive to catheter failure and are not capable of detecting the signs of failure themselves.

A method for managing delivery of medication to a patient including medication dosage control and medication flow rate control for the patient. The method comprises controlling flow rate of the medication to be delivered to the patient through a needle that is subcutaneously inserted into the patient including: monitoring glucose levels in the patient using a continuous glucose monitoring device; converting the glucose levels from the continuous glucose monitoring device into instructions by control algorithms within a microcontroller unit; commanding a pumping unit to deliver the medication through the needle at a flow rate based on the converted instructions; and delivering the medication through the needle into the patient at the flow rate; and adjusting the flow rate continually to reduce a difference between actual flow rate measured off of the pumping unit and a converted flow rate from the continuous glucose monitoring device.

The present invention provides a closed loop control method in an artificial pancreas and a system using the method, comprising sensing an activity level of a patient by at least one motion sensor and providing signals to at least one processer; then adjusting a series of related algorithms depending partly on the signals by the processer to provide more accurate and reliable data that is the basis of desirable treatment plans, and sending corresponding instructions by the processer for automatic operations of the artificial pancreas to realize a closed loop control.

The present disclosure provides methods of measuring of an analyte in a subject to remove a measurement artifact by using a forecasting model to determine the true analyst concentration in a subject. Also herein, the present disclosure provides parameters and models to estimate the true analyte concentration in a subject.

Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

A method and apparatus used to prevent brain death by use of rapid and safe cooling of the brain is disclosed. The cisterna magna is accessed through a patient's neck and cooled artificial cerebrospinal fluid (aCSF) is circulated about spaces within the brain and in a subarachnoid space surrounding the brain by entering the cisterna magna with an entry through the neck of the patient with a specially designed needle/cannula which allows the flow of cooled aCSF about the brain. aCSF exits from an opening in the skull where a temperature/pressure sensor is placed. Data is sent to a computer-controlled motorized system that pumps cooled aCSF to the needle/cannula placed in the cisterna magna. The pumping of aCSF is controlled to maintain a predetermined temperature and/or pressure of the exiting aCSF.

The disclosed systems and methods are configurable central nervous system (CNS) delivery solutions for therapeutics, such as genetic medicines. The systems and methods first infuse a therapeutic bolus within intrathecal space and subsequently infuse a flush fluid to move the therapeutic bolus rostrally toward a target area and achieve a desired spread in the spine and/or brain. The second location can be at a location caudal to the delivery location of the therapeutic bolus.

A medical device system. The system includes a first medical device, a first remote interface, and a second remote interface in communication with the first remote interface and the first medical device, wherein the first medical device sends a command to the first medical device through the second remote interface, and wherein when the second remote interface receives the command, the command must be confirmed by the second remote interface before the command is send by the second remote interface to the first medical device.

Systems and methods are disclosed herein for providing a configuration code for customizing a glucose level control system for at least an initial period. The configuration code can be based on one or more dosing parameters from a tracked medicament therapy administered to a subject over a tracking period by the glucose level control system. The configuration code includes encoded dosing parameters including a correction dosing parameter based on at least some of the correction boluses of medicament administered during the tracking period, a food intake dosing parameter comprising an indication of a food intake bolus size of medicament based on one or more food intake boluses provided during the tracking period, and a basal dosing parameter based on at least some of the basal doses of medicament administered during the tracking period.

A patch-sized fluid delivery device may include a reusable portion and a disposable portion. The disposable portion may include components that come into contact with the fluid, while the reusable portion may include only components that do not come into contact with the fluid. Redundant systems, such as redundant controllers, power sources, motor actuators, and alarms, may be provided. Alternatively or additionally, certain components can be multi-functional, such a microphones and loudspeakers that may be used for both acoustic volume sensing and for other functions and a coil that may be used as both an inductive coupler for a battery recharger and an antenna for a wireless transceiver. Various types of network interfaces may be provided in order to allow for remote control and monitoring of the device.